Effects of SGLT-2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine-N-Oxide in Patients With Type-2 Diabetes.
Katja B Zimmer, Arne Gessner, Dennis Kannenkeril et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial investigated the effects of SGLT-2 inhibitors empagliflozin and dapagliflozin on plasma levels and renal clearance of trimethylamine-N-oxide (TMAO) in patients with Type 2 diabetes. In a total of 123 patients, TMAO plasma levels increased by 11.5% after SGLT-2 inhibitor treatment compared to placebo (p = 0.006), while renal clearance of TMAO decreased by 10.3% (p = 0.048).
Key findings
- TMAO plasma levels were 11.5% higher after SGLT-2 inhibitor treatment compared to placebo (p = 0.006).
- Renal clearance of TMAO decreased by 10.3% after SGLT-2 inhibitor treatment (p = 0.048).
- In the dapagliflozin trial, TMAO plasma concentration was 23.4% higher (p = 0.021).
- Dapagliflozin treatment resulted in a 22.6% lower renal clearance of TMAO (p = 0.025).
Why it matters
The findings suggest that SGLT-2 inhibitors may influence TMAO levels, a marker associated with cardiovascular risk. Understanding this relationship is crucial for evaluating the overall clinical benefits of these medications in managing Type 2 diabetes and associated cardiovascular conditions.